Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
13.65 USD | -1.09% | -7.27% | +27.57% |
May. 20 | Immunome Completes Purchase of Antibodies From Atreca | MT |
May. 20 | Immunome, Inc. completed the acquisition of Substantially all Assets of Atreca, Inc.. | CI |
Business Summary
Number of employees: 55
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Biotechnology
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | nan % | 14 | 100.0 % | - |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Max Rosett
DFI | Director of Finance/CFO | 34 | 23-10-01 |
Bob Lechleider
CTO | Chief Tech/Sci/R&D Officer | 63 | 23-10-18 |
Matthew Robinson
CTO | Chief Tech/Sci/R&D Officer | 55 | 16-02-29 |
Jack Higgins
CTO | Chief Tech/Sci/R&D Officer | 45 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
Bruce Turner
PRN | Corporate Officer/Principal | 60 | 23-10-01 |
Sandra Stoneman
LAW | General Counsel | 51 | 20-12-09 |
Kinney Horn
PRN | Corporate Officer/Principal | 49 | Jan. 31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Carol Schafer
BRD | Director/Board Member | 60 | Jan. 01 |
Director/Board Member | 70 | Nov. 06 | |
Clay Siegall
CEO | Chief Executive Officer | 63 | 23-10-01 |
Philip Wagenheim
BRD | Director/Board Member | 53 | 16-12-31 |
James Boylan
BRD | Director/Board Member | 57 | 23-10-01 |
Isaac Barchas
BRD | Director/Board Member | 56 | 23-10-01 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 59,968,868 | 49,826,623 ( 83.09 %) | 0 | 83.09 % |
Company contact information
Sector
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+27.38% | 827M | |
+8.37% | 115B | |
+13.10% | 107B | |
-12.81% | 22.31B | |
-3.99% | 21.6B | |
-7.02% | 18.23B | |
-39.93% | 17.62B | |
+6.17% | 14.26B | |
+34.14% | 12.37B | |
-28.68% | 8.28B |
- Stock Market
- Equities
- IMNM Stock
- Company Immunome, Inc.